Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity

• Published in: Radiation oncology (London, England) England), 2023-05, Vol.18 (1), p.89-89, Article 89
• Main Authors: Gao, Zhiru, Zhao, Qian, Xu, Yiyue, Wang, Linlin
• Format: Article
• Language: English
• Subjects: Analysis; Anticancer properties; Antigen (tumor-associated); Antigens; Apoptosis; Biomarkers; Cancer; Cancer therapies; Care and treatment; Cell cycle; Cell Proliferation; Clinical trials; Cytokines; Cytotoxicity; Diagnosis; DNA damage; DNA methylation; Drug dosages; Drug resistance; Effectiveness; Epigenetics; Genetic screening; Health aspects; Human papillomavirus; Humans; Hypoxia; Immune checkpoint blockade; Immune system; Immunology; Immunotherapy; Impact prediction; Ionizing radiation; Kinases; Lung cancer; Lymphocytes; Medical prognosis; Metastasis; Methods; Mutation; Necrosis; Patient outcomes; Proteins; Radiation Oncology; Radiation therapy; Radiation Tolerance; Radiation, Ionizing; Radiosensitivity; Radiosensitivity index; Radiotherapy; Reactive oxygen species; Review; Tumor cells; Tumors
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-023-02278-5

Cancer treatment is gradually entering an era of precision, with multitude studies in gene testing and immunotherapy. Tumor cells can be recognized and eliminated by the immune system through the expression of tumor-associated antigens, but when the cancer escapes or otherwise suppresses immunity, the balance between cancer cell proliferation and immune-induced cancer cell killing may be interrupted, resulting in tumor proliferation and progression. There has been significant attention to combining conventional cancer therapies (i.e., radiotherapy) with immunotherapy as opposed to treatment alone. The combination of radio-immunotherapy has been demonstrated in both basic research and clinical trials to provide more effective anti-tumor responses. However, the absolute benefits of radio-immunotherapy are dependent on individual characteristics and not all patients can benefit from radio-immunotherapy. At present, there are numerous articles about exploring the optimal models for combination radio-immunotherapy, but the factors affecting the efficacy of the combination, especially with regard to radiosensitivity remain inconclusive. Radiosensitivity is a measure of the response of cells, tissues, or individuals to ionizing radiation, and various studies have shown that the radiosensitivity index (RSI) will be a potential biomarker for predicting the efficacy of combination radio-immunotherapy. The purpose of this review is to focus on the factors that influence and predict the radiosensitivity of tumor cells, and to evaluate the impact and predictive significance of radiosensitivity on the efficacy of radio-immunotherapy combination.